Study guide
14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
Key Takeaways Explain This Topic AI
Infertility is failure to conceive after 12 months of regular unprotected intercourse, or 6 months at age 35 or older, with immediate evaluation when oligomenorrhea, known tubal or uterine disease, or male factor is present.
A midluteal serum progesterone above 3 ng/mL drawn about 7 days before the expected period confirms that ovulation occurred.
Hysterosalpingography is the first-line test of tubal patency, while saline infusion sonohysterography gives the best view of the endometrial cavity but assesses no tubes.
Hysterosalpingography and sonohysterography are scheduled on cycle days 5 to 10 with pregnancy excluded, and are contraindicated in pregnancy, active pelvic infection, and active bleeding.
WHO 6th edition semen reference limits are volume 1.4 mL, concentration 16 million per mL, total motility 42 percent, progressive motility 30 percent, and normal morphology 4 percent.
Last updated: September 2026
Defining and Timing the Evaluation
Infertility is classically defined as failure to conceive after 12 months of regular unprotected intercourse , or after 6 months for patients aged 35 and older . ASRM has broadened the definition to include anyone who needs medical intervention — donor gametes or embryos — to conceive, which brings single patients and same-sex couples inside the definition rather than outside it.
Evaluate immediately, without waiting , when any of these is present: oligomenorrhea or amenorrhea, known or suspected tubal disease or uterine anomaly, stage III–IV endometriosis, prior pelvic infection or surgery, known male-factor infertility, age 40 or older, or a history of chemotherapy or pelvic radiation.
The initial evaluation is squarely within midwifery scope; it is the treatment that is referred.
The Three-Domain Initial Workup
Every basic evaluation answers three questions: is she ovulating, is the anatomy patent, and is there sperm?
1. Ovulatory Function
Cycle history is the best screening test. Regular cycles of 24 to 38 days with consistent molimina are ~95% predictive of ovulation.
Midluteal serum progesterone drawn about 7 days before the expected period (day 21 of a 28-day cycle): a value above 3 ng/mL confirms ovulation occurred.
Urinary LH ovulation predictor kits detect the surge 24 to 36 hours before ovulation.
Ovarian reserve testing for patients 35 and older or with risk factors: anti-Müllerian hormone (AMH) , antral follicle count on transvaginal ultrasound, and cycle day 3 FSH with estradiol . Reserve testing predicts response to stimulation — it does not predict natural fertility and should never be presented to a patient as a "fertility score."
Add TSH and prolactin when cycles are irregular; check androgens if hirsutism or acne suggests PCOS.
2. Uterine Cavity and Tubal Patency
Study What It Shows When to Order
Hysterosalpingography (HSG) Tubal patency plus a silhouette of the cavity; uses iodinated contrast under fluoroscopy First-line tubal assessment; oil-soluble contrast has a modest therapeutic effect on subsequent conception
Saline infusion sonohysterography (sonohysterogram / SIS) The best view of the endometrial cavity — polyps, submucosal myomas, synechiae, septa Suspected intracavitary lesion, abnormal uterine bleeding with a thickened or irregular stripe, recurrent pregnancy loss, pre-operative planning. Does not assess tubal patency
Hysterosalpingo-contrast sonography (HyCoSy) Tubal patency plus cavity, without ionizing radiation Where available and the sonographer is experienced
Transvaginal pelvic ultrasound Myomas, ovarian cysts and endometriomas, antral follicle count, adenomyosis Baseline for nearly every gynecologic complaint
Laparoscopy Direct visualization; diagnoses and treats endometriosis and adhesions Reserved for suspected endometriosis or abnormal non-invasive findings
Timing and safety for HSG and sonohysterography: schedule in the early follicular phase, roughly cycle days 5 to 10 , after bleeding has stopped and before ovulation, with pregnancy excluded. Contraindications: pregnancy, active pelvic infection or untreated cervicitis, and active uterine bleeding. Premedicate with an NSAID; doxycycline prophylaxis is used when tubal dilation is found or a history of pelvic infection exists.
3. Semen Analysis
A semen analysis is part of the initial workup, not a later step — male factor contributes to roughly 40–50% of cases and is the cheapest thing to rule out.
Collect after 2 to 7 days of abstinence ; repeat an abnormal result after at least 4 weeks.
WHO 6th edition (2021) lower reference limits: volume 1.4 mL , concentration 16 million/mL , total count 39 million , total motility 42% , progressive motility 30% , normal morphology 4% .
These are reference limits from fertile men, not thresholds of sterility — pregnancies occur below them and fail above them.
Preconception Optimization and Referral
While the workup proceeds, address what is modifiable:
400 to 800 mcg folic acid daily, rubella and varicella immunity, hepatitis B and STI screening, and carrier screening.
Weight: both a BMI below 18.5 and above 30 impair ovulation; a 5–10% weight reduction restores ovulatory cycles in many patients with PCOS.
Tobacco cessation — smoking accelerates follicular depletion and reduces IVF success; limit alcohol and high-dose caffeine.
Review medications for teratogens and for agents that impair ovulation or spermatogenesis (NSAIDs at ovulation, testosterone supplementation in the male partner, which suppresses spermatogenesis).
Advise intercourse every 1 to 2 days during the fertile window , the 6 days ending on the day of ovulation; lubricants other than mineral-oil or hydroxyethylcellulose-based products can impair sperm motility.
Refer to reproductive endocrinology and infertility once the basic evaluation is complete, or sooner for age 40 or older, amenorrhea, known tubal occlusion, severe male factor, or recurrent pregnancy loss.
Endocrine Evaluation of Ovulatory Dysfunction
When the history or the midluteal progesterone points to anovulation, the next step is to identify which anovulation, because the treatments diverge completely:
- Test Abnormal result What it identifies
- TSH Elevated Hypothyroidism — a common, fully reversible cause of anovulation and of early pregnancy loss
Prolactin Elevated on a properly drawn specimen Hyperprolactinemia from a pituitary adenoma, medication, hypothyroidism, or stress; suppresses GnRH pulsatility
FSH and estradiol, early follicular High FSH with low estradiol Diminished ovarian reserve or primary ovarian insufficiency
FSH and LH Both low, with low estradiol Hypogonadotropic hypogonadism — the pattern of functional hypothalamic amenorrhea from energy deficit, excessive exercise, or eating disorder
Total testosterone, DHEA-S, 17-hydroxyprogesterone Elevated Hyperandrogenism: polycystic ovary syndrome, non-classic congenital adrenal hyperplasia, or an androgen-secreting tumor
Draw prolactin in the morning, fasting, and without recent breast stimulation, exercise, or intercourse, and repeat a mildly elevated value before acting on it — a single high result is frequently an artifact of the draw conditions.
Modifiable Factors Worth More Than Most Testing
These are within midwifery scope, cost nothing, and are routinely skipped in the rush to imaging:
Intercourse timing. The fertile window is the 5 days before ovulation plus the day of ovulation , and intercourse every 1 to 2 days across that window is as effective as any timing method. Couples who "save up" for a single perfectly timed day conceive less often, not more.
Weight at either extreme disrupts ovulation; in anovulatory patients with obesity, modest weight loss can restore ovulation without any medication.
Tobacco accelerates follicular depletion and advances menopause; cessation is the single highest-yield intervention in a smoker.
Alcohol, cannabis, and anabolic steroid use all impair fertility, and anabolic steroids suppress spermatogenesis for months after they are stopped.
Folic acid supplementation and a review of teratogenic medications belong in the first infertility visit, not in the first prenatal visit — by then the exposure has already happened.
Male Factor & Referral Thresholds
Male factor contributes to roughly half of infertility, so the semen analysis is obtained at the start of the evaluation, in parallel with the female workup , never after it. Collect after 2 to 7 days of abstinence , and repeat any abnormal result after at least a few weeks before acting on it, since a single specimen is affected by recent illness, fever, and abstinence interval. An abnormality confirmed on repeat testing warrants referral to urology or reproductive endocrinology.
Also address fertility preservation counseling before any gonadotoxic therapy — chemotherapy, pelvic radiation, or planned gonadectomy — and before starting gender-affirming hormone therapy in a patient who may want genetic children. The conversation has to happen before treatment begins; afterward there is nothing to preserve.